SI1773312T1 - Sestavek, ki vsebuje statine in maščobne kisline omega-3 - Google Patents

Sestavek, ki vsebuje statine in maščobne kisline omega-3

Info

Publication number
SI1773312T1
SI1773312T1 SI200531865T SI200531865T SI1773312T1 SI 1773312 T1 SI1773312 T1 SI 1773312T1 SI 200531865 T SI200531865 T SI 200531865T SI 200531865 T SI200531865 T SI 200531865T SI 1773312 T1 SI1773312 T1 SI 1773312T1
Authority
SI
Slovenia
Prior art keywords
omega
fatty acids
composition containing
containing statins
statins
Prior art date
Application number
SI200531865T
Other languages
English (en)
Slovenian (sl)
Inventor
Claudio Cavazza
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of SI1773312T1 publication Critical patent/SI1773312T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200531865T 2004-08-03 2005-07-19 Sestavek, ki vsebuje statine in maščobne kisline omega-3 SI1773312T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000395A ITRM20040395A1 (it) 2004-08-03 2004-08-03 Composizione comprendente statine e acidi grassi omega 3.
PCT/IT2005/000414 WO2006013602A1 (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids
EP05769486.1A EP1773312B1 (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids

Publications (1)

Publication Number Publication Date
SI1773312T1 true SI1773312T1 (sl) 2014-08-29

Family

ID=35124288

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531865T SI1773312T1 (sl) 2004-08-03 2005-07-19 Sestavek, ki vsebuje statine in maščobne kisline omega-3

Country Status (21)

Country Link
US (1) US8853229B2 (https=)
EP (1) EP1773312B1 (https=)
JP (1) JP5103179B2 (https=)
KR (1) KR101355122B1 (https=)
CN (1) CN1993119B (https=)
AU (1) AU2005268402B2 (https=)
BR (1) BRPI0514026A (https=)
CA (1) CA2573000C (https=)
CY (1) CY1115416T1 (https=)
DK (1) DK1773312T3 (https=)
EA (1) EA014444B1 (https=)
ES (1) ES2481169T3 (https=)
IL (1) IL180602A (https=)
IT (1) ITRM20040395A1 (https=)
MX (1) MX2007001009A (https=)
NZ (1) NZ552396A (https=)
PL (1) PL1773312T3 (https=)
PT (1) PT1773312E (https=)
SI (1) SI1773312T1 (https=)
WO (1) WO2006013602A1 (https=)
ZA (1) ZA200701816B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
DE102004063638A1 (de) * 2004-12-31 2006-07-13 Biosyn Arzneimittel Gmbh Selen-haltige Medikamente zur Prophylaxe oder Therapie von endothelialen Gefäßerkrankungen
KR20070108945A (ko) * 2005-03-08 2007-11-13 릴라이언트 파마슈티컬스 인코퍼레이티드 스타틴과 오메가-3 지방산 및 그 조합물을 이용한 치료
CN101365431A (zh) * 2005-10-14 2009-02-11 帝斯曼知识产权资产管理有限公司 包含白藜芦醇的营养药物组合物的新颖用途
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US20080085911A1 (en) 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
KR101383006B1 (ko) 2009-02-10 2014-04-08 아마린 파마, 인크. 고중성지방혈증 치료 방법
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
RU2539921C2 (ru) * 2009-06-12 2015-01-27 Каланус Ас Композиция из жира веслоногих ракообразных, препарат, содержащий эту композицию, включающую жир, ее применение для снижения накопления висцерального жира, улучшения толерантности к глюкозе, предотвращения или лечения заболеваний и расстройств, связанных с ожирением
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
MX2012006993A (es) 2009-12-23 2012-07-30 Defiante Farmaceutica Sa Composicion de combinacion util para el tratamiento de enfermedades cardiovasculares.
US8557236B2 (en) * 2010-02-09 2013-10-15 Vascure Natural LLC Cardiovascular support supplement and compositions and methods thereof
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
RU2543539C2 (ru) 2010-12-20 2015-03-10 Хилл'С Пет Ньютришн, Инк. Кормовые композиции для домашних животных, вызывающие чувство сытости
AU2015201809B2 (en) * 2010-12-20 2016-09-29 Hill's Pet Nutrition, Inc. Pet food compositions for inducing a satiety response
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
JP6359517B2 (ja) * 2012-03-30 2018-07-18 サンシリオ アンド カンパニー, インコーポレイテッドSancilio & Company, Inc. ω−３脂肪酸エステル組成物
WO2013149258A2 (en) * 2012-03-30 2013-10-03 Charles Drew University of Medicine and Science Compositions and methods for treating or preventing metabolic syndrome disorders
EP4338805B1 (en) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
WO2015003246A1 (en) * 2013-07-09 2015-01-15 Mcmaster University Combination of a statin with an inflammasome inhibitor
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
RU2554806C1 (ru) * 2014-07-29 2015-06-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Способ коррекции повышенного уровня тревоги и депрессии у пациентов с артериальной гипертонией на фоне сахарного диабета 2 типа
CN104922160A (zh) * 2015-05-22 2015-09-23 舟山三合生物科技有限公司 他汀与Omega-3脂肪酸和辅酶Q10复配的组合物及其应用
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
ITUA20162575A1 (it) 2016-04-13 2017-10-13 S&R Farm S P A Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US12171728B2 (en) 2018-04-16 2024-12-24 S&R Farmaceutici S.P.A. Mixture of resveratrol supported on metal hydroxide and non-supported pure resveratrol for treating female fertility
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1055638C (zh) * 1995-07-14 2000-08-23 李江 富硒虫草口服液及其制备方法
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US20030228393A1 (en) * 2002-05-31 2003-12-11 Zhao Iris Ginron Multi-phase food & beverage
CN1061259C (zh) * 1998-11-24 2001-01-31 彭素萍 藜蒿中生物活性物质的富集物及用途
CA2427618A1 (en) 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
US20050002992A1 (en) * 2003-06-17 2005-01-06 Mccleary Edward Larry Foods, beverages, condiments, spices and salad dressings with specialized supplements
US20020182585A1 (en) 2001-01-10 2002-12-05 George Kindness Combination and method using EDTA, cystine, zinc and selenium for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20040018248A1 (en) * 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
US6855353B2 (en) * 2002-03-08 2005-02-15 Yaguang Liu Method for producing antioxidant and prevention of cancer
EP1536698A1 (en) * 2002-08-23 2005-06-08 DSM IP Assets B.V. Novel nutraceutical compositions comprising biotin
EP2384750A1 (en) * 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
EP1558244A2 (en) 2002-11-07 2005-08-03 DSM IP Assets B.V. Novel nutraceutical compositions comprising epigallocatechin gallate

Also Published As

Publication number Publication date
BRPI0514026A (pt) 2008-05-27
PT1773312E (pt) 2014-07-25
ITRM20040395A1 (it) 2004-11-03
CN1993119A (zh) 2007-07-04
AU2005268402A1 (en) 2006-02-09
EP1773312B1 (en) 2014-05-07
HK1105871A1 (en) 2008-02-29
EA200700240A1 (ru) 2007-06-29
US8853229B2 (en) 2014-10-07
CA2573000C (en) 2014-03-11
ZA200701816B (en) 2008-07-30
EA014444B1 (ru) 2010-12-30
PL1773312T3 (pl) 2014-09-30
CY1115416T1 (el) 2017-01-04
CA2573000A1 (en) 2006-02-09
MX2007001009A (es) 2007-04-16
DK1773312T3 (da) 2014-07-21
IL180602A0 (en) 2008-03-20
IL180602A (en) 2015-06-30
NZ552396A (en) 2009-08-28
ES2481169T3 (es) 2014-07-29
KR20070058460A (ko) 2007-06-08
EP1773312A1 (en) 2007-04-18
JP2008509132A (ja) 2008-03-27
AU2005268402B2 (en) 2010-08-26
JP5103179B2 (ja) 2012-12-19
CN1993119B (zh) 2011-04-06
WO2006013602A1 (en) 2006-02-09
US20080089876A1 (en) 2008-04-17
KR101355122B1 (ko) 2014-02-04

Similar Documents

Publication Publication Date Title
IL180602A0 (en) Composition containing statins and omega-3 fatty acids
EP1801096B8 (en) Polyglycerol fatty acid ester and composition containing same
IL174925A0 (en) Glycerophospholipids containing omega -3 and omega-6 fatty acids
EP2083815A4 (en) STATIN AND OMEGA-3 FATTY ACIDS FOR REDUCING APO-B MIRRORS
IL186297A0 (en) N-alkylcarbonyl-amino acid ester and n-alkylcarbonyl-amino lactone compounds and their use
IL183246A0 (en) Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
EP1782789A4 (en) LIQUID ESTER COMPOSITION AND COSMETIC PREPARATION CONTAINING THE SAME
PL1699449T3 (pl) Zastosowanie kompozycji kwasów tłuszczowych obejmującej co najmniej jeden z EPA i DHA lub jakąkolwiek ich kombinację
PL377614A1 (pl) Kompozycje zawierające kwasy tłuszczowe i aminokwasy
EP1830830A4 (en) OMEGA-3 FATTY ACIDS AND DYSLIPIDEMIC MEANS FOR LIPID THERAPY
EP2089014A4 (en) OMEGA-3 FATTY ACIDS AND DYSLIPIDEMIC AGENT FOR REDUCING APO-B LEVELS
ZA200802457B (en) Method for extending the shelf-life of food compositions containing polyunsaturated fatty acids
IL205362A0 (en) Medium - chain length fatty acids and glycerides as nephroprotection agents
EP1709952B8 (en) Composition containing polyglycerol/medium-chain fatty acid ester
PL2214638T3 (pl) Kompozycja zawierająca wielonienasycone kwasy tłuszczowe i węgiel aktywny
EP1617830A4 (en) ESTERIFIED FATTY ACID COMPOSITION
ZA200702801B (en) Pharmaceutical composition comprising temozolomide ester
PL1765318T3 (pl) Średniołańcuchowe kwasy tłuszczowe przydatne jako środki przeciwdrobnoustrojowe
GB2444896B (en) Compositions comprising polyunsaturated fatty acids
ZA200609727B (en) Carbonylation of ester
IL194906A0 (en) Triphenylmethylphosphonate ester derivatives and pharmaceutical compositions containing the same
GB2428678B (en) Glyceride compounds and uses thereof
DE602004028454D1 (de) Mit metallionen ausgetauschte feststoffe zur verwevon fettsäuren und deren alkylestern
HUP0402490A2 (en) Antiviral and immunestimulant pharmaceutical composition containing polyunsaturated fatty acid esters
HK1111633A (en) Treatment with statin and omega-3 fatty acids and a combination product thereof